| abstract |
Bispecific antibodies are disclosed that include a first antigen binding domain that specifically binds to an HIV-1 envelope protein (such as gp120 or gp41), and a second antigen binding domain that is T cell activating and HIV-1 -activating, such as an scFv that specifically binds to CD3. In some embodiments, the bispecific antibody includes a scFv that specifically binds to an HIV-1 envelope protein (such as gp120 or gp41) and a scFv that that is T cell activating and HIV-1 -activating, such as an scFv that specifically binds to CD3. In additional embodiments, the bispecific antibody includes a Fab that specifically binds to an HIV-1 envelope protein (such as gp120 or gp41) and a scFv that that is T cell activating and HIV-1 -activating, such as an scFv that specifically binds to CD3. Multispecific antibodies are also disclosed that include these bispecific antibodies. Methods of using these bispecific antibodies, multispecific antibodies and nucleic acids encoding these antibodies are also disclosed. |